Jiuwei Cui

814 total citations
20 papers, 115 citations indexed

About

Jiuwei Cui is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jiuwei Cui has authored 20 papers receiving a total of 115 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jiuwei Cui's work include HER2/EGFR in Cancer Research (4 papers), Lung Cancer Treatments and Mutations (3 papers) and DNA Repair Mechanisms (2 papers). Jiuwei Cui is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Lung Cancer Treatments and Mutations (3 papers) and DNA Repair Mechanisms (2 papers). Jiuwei Cui collaborates with scholars based in China, United States and Canada. Jiuwei Cui's co-authors include Zhi Li, Wei Li, Fujun Han, Huimin Tian, Lin Jia, Lihua Dong, Yuyu Zhang, Ziling Liu, Ou Bai and Yuying Li and has published in prestigious journals such as Journal of Clinical Oncology, Applied Energy and Journal of Hepatology.

In The Last Decade

Jiuwei Cui

18 papers receiving 114 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiuwei Cui China 7 49 42 36 31 13 20 115
Xiaolong Cheng China 5 76 1.6× 35 0.8× 30 0.8× 19 0.6× 6 0.5× 9 123
Jeremy S. Gresham United States 4 48 1.0× 42 1.0× 35 1.0× 28 0.9× 14 1.1× 5 99
Shucai Zhang China 9 110 2.2× 61 1.5× 49 1.4× 36 1.2× 11 0.8× 16 159
Olena M. Vaske United States 7 60 1.2× 27 0.6× 32 0.9× 13 0.4× 8 0.6× 18 116
Ιωάννα Ακρίδα Greece 7 63 1.3× 57 1.4× 67 1.9× 20 0.6× 6 0.5× 13 158
Saya H. Ebbesen United States 3 90 1.8× 45 1.1× 23 0.6× 13 0.4× 7 0.5× 3 123
Victoria Damerell South Africa 7 87 1.8× 52 1.2× 30 0.8× 45 1.5× 4 0.3× 8 161
Melanie Ongchin United States 7 91 1.9× 52 1.2× 38 1.1× 14 0.5× 9 0.7× 14 167
Ekaterini Christina Tampaki Switzerland 8 56 1.1× 61 1.5× 32 0.9× 12 0.4× 4 0.3× 15 147
Anna McLean Australia 4 94 1.9× 88 2.1× 63 1.8× 70 2.3× 11 0.8× 6 204

Countries citing papers authored by Jiuwei Cui

Since Specialization
Citations

This map shows the geographic impact of Jiuwei Cui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiuwei Cui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiuwei Cui more than expected).

Fields of papers citing papers by Jiuwei Cui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiuwei Cui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiuwei Cui. The network helps show where Jiuwei Cui may publish in the future.

Co-authorship network of co-authors of Jiuwei Cui

This figure shows the co-authorship network connecting the top 25 collaborators of Jiuwei Cui. A scholar is included among the top collaborators of Jiuwei Cui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiuwei Cui. Jiuwei Cui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cui, Jiuwei, et al.. (2025). Multi-stage adaptive expansion of EV charging stations considering impacts from the transportation network and power grid. Applied Energy. 386. 125544–125544. 4 indexed citations
2.
3.
4.
Lisberg, Aaron, Shun Lu, Erika Hamilton, et al.. (2025). DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.. Journal of Clinical Oncology. 43(16_suppl). 3000–3000.
5.
6.
Zhou, Jianya, Xueli Bai, Yiwen Chen, et al.. (2025). First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 43(16_suppl). 8509–8509. 2 indexed citations
7.
Zhang, Shaobo, Hongxia Xu, Wěi Li, et al.. (2024). Development and validation of an inflammatory biomarkers model to predict gastric cancer prognosis: a multi-center cohort study in China. BMC Cancer. 24(1). 711–711. 1 indexed citations
8.
Wang, Yang, Ming Zhang, Jiahui Liu, et al.. (2024). YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis. JCI Insight. 9(24). 8 indexed citations
9.
Wang, Xuan, Hongming Pan, Jiuwei Cui, et al.. (2024). SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma. Immunotherapy. 16(4). 243–256. 6 indexed citations
10.
Li, Zhi & Jiuwei Cui. (2023). Targeting the lactic acid metabolic pathway for antitumor therapy. Molecular Therapy — Oncolytics. 31. 100740–100740. 31 indexed citations
11.
Xu, Jianming, Jiuwei Cui, Haiping Jiang, Yan Zeng, & Xiuyu Julie Cong. (2023). Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients. Cancer Medicine. 12(7). 7762–7771. 2 indexed citations
12.
Guo, Hanfei, Wenqian Li, Ye Guo, Naifei Chen, & Jiuwei Cui. (2023). Molecular classification of small cell lung cancer subtypes: Characteristics, prognostic factors, and clinical translation. Chinese Medical Journal. 137(2). 130–139. 4 indexed citations
13.
Yang, Ruohan, et al.. (2023). Case report: Hilar metastasis of breast cancer: A single-center retrospective case-control study. Frontiers in Surgery. 10. 1025287–1025287.
14.
15.
Guo, Ye, Ying Cheng, Zhen Wang, et al.. (2023). Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2536–2536. 7 indexed citations
16.
Liu, Xiangliang, Wei Ji, Wenxin Zhang, et al.. (2022). Effects of Diabetes on Inflammatory Status and Prognosis in Cancer Patients. Frontiers in Nutrition. 9. 792577–792577. 5 indexed citations
17.
Yang, Ruohan, et al.. (2022). Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study. Frontiers in Oncology. 12. 1048781–1048781. 11 indexed citations
18.
Zhao, Hongyun, Yuxiang Ma, Ying Cheng, et al.. (2021). MA02.06 Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC. Journal of Thoracic Oncology. 16(10). S891–S891. 5 indexed citations
19.
Zhang, Yuyu, Ziling Liu, Mengmeng Wang, et al.. (2016). Single Nucleotide Polymorphism rs1801516 in Ataxia Telangiectasia-Mutated Gene Predicts Late Fibrosis in Cancer Patients After Radiotherapy. Medicine. 95(14). e3267–e3267. 17 indexed citations
20.
Li, Yuying, Ou Bai, Jiuwei Cui, & Wei Li. (2015). Genetic polymorphisms in the DNA repair gene, XRCC1 associate with non-Hodgkin lymphoma susceptibility: A systematic review and meta-analysis. European Journal of Medical Genetics. 59(2). 91–103. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaolong Cheng Breakdown of academic impact, for papers by Jeremy S. Gresham Breakdown of academic impact, for papers by Shucai Zhang Breakdown of academic impact, for papers by Olena M. Vaske Breakdown of academic impact, for papers by Ιωάννα Ακρίδα Breakdown of academic impact, for papers by Saya H. Ebbesen Breakdown of academic impact, for papers by Victoria Damerell Breakdown of academic impact, for papers by Melanie Ongchin Breakdown of academic impact, for papers by Ekaterini Christina Tampaki Breakdown of academic impact, for papers by Anna McLean
Rankless by CCL
2026